BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry 2022;27:1898-907. [PMID: 34997196 DOI: 10.1038/s41380-021-01432-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 38.0] [Reference Citation Analysis]
Number Citing Articles
1 Kirenga BJ, Mugenyi L, Sánchez-Rico M, Kyobe H, Muttamba W, Mugume R, Mwesigwa E, Kalimo E, Nyombi V, Segawa I, Namakula LO, Sekibira R, Kabweru W, Byanyima R, Aanyu H, Byakika-Kibwika P, Mwebesa HG, Hoertel N, Bazeyo W. Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study. Mol Psychiatry 2023;:1-8. [PMID: 36869228 DOI: 10.1038/s41380-023-02004-3] [Reference Citation Analysis]
2 Brown KA, Zanos P, Powels CF, Fix CJ, Michaelides M, Pereira EFR, Moaddel R, Gould TD. Ketamine preservative benzethonium chloride potentiates hippocampal synaptic transmission and binds neurotransmitter receptors and transporters. Neuropharmacology 2023;225:109403. [PMID: 36565852 DOI: 10.1016/j.neuropharm.2022.109403] [Reference Citation Analysis]
3 Chapola H, de Bastiani MA, Duarte MM, Freitas MB, Schuster JS, de Vargas DM, Klamt F. A comparative study of COVID-19 transcriptional signatures between clinical samples and preclinical cell models in the search for disease master regulators and drug repositioning candidates. Virus Res 2023;326:199053. [PMID: 36709793 DOI: 10.1016/j.virusres.2023.199053] [Reference Citation Analysis]
4 Cobos-Campos R, Sáez de Lafuente-Moríñigo A, Cordero-Guevara JA, Bermúdez-Ampudia C, Apiñaniz A, Argaluza J, Parraza N. Antidepressants Are Associated With a Reduction in the Risk of Death in COVID-19 Disease Patients. Am J Ther 2023. [PMID: 36856572 DOI: 10.1097/MJT.0000000000001618] [Reference Citation Analysis]
5 Hashimoto K. Arketamine for cognitive impairment in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci 2023;:1-13. [PMID: 36786865 DOI: 10.1007/s00406-023-01570-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bhimraj A, Gallagher JC. Lack of Benefit of Fluvoxamine for COVID-19. JAMA 2023;329:291-2. [PMID: 36633871 DOI: 10.1001/jama.2022.23954] [Reference Citation Analysis]
7 Munguia-Galaviz FJ, Miranda-Diaz AG, Cardenas-Sosa MA, Echavarria R. Sigma-1 Receptor Signaling: In Search of New Therapeutic Alternatives for Cardiovascular and Renal Diseases. Int J Mol Sci 2023;24. [PMID: 36768323 DOI: 10.3390/ijms24031997] [Reference Citation Analysis]
8 Deng J, Rayner D, Ramaraju HB, Abbas U, Garcia C, Heybati K, Zhou F, Huang E, Park YJ, Moskalyk M. Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis. Clin Microbiol Infect 2023:S1198-743X(23)00032-0. [PMID: 36657488 DOI: 10.1016/j.cmi.2023.01.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Groves H, Allen U, Morris S. Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. Clinical Management of Pediatric COVID-19 2023. [DOI: 10.1016/b978-0-323-95059-6.00006-1] [Reference Citation Analysis]
10 Panda SK, Gupta PSS, Rana MK. Potential targets of severe acute respiratory syndrome coronavirus 2 of clinical drug fluvoxamine: Docking and molecular dynamics studies to elucidate viral action. Cell Biochem Funct 2023;41:98-111. [PMID: 36478589 DOI: 10.1002/cbf.3766] [Reference Citation Analysis]
11 Johnson DM, Brasel T, Massey S, Garron T, Grimes M, Smith J, Torres M, Wallace S, Villasante-Tezanos A, Beasley DW, Comer JE. Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model. Antiviral Res 2023;209:105492. [PMID: 36535309 DOI: 10.1016/j.antiviral.2022.105492] [Reference Citation Analysis]
12 Zhang F, Gong W, Cui Z, Li J, Lu Y. Rhabdomyolysis in a male adolescent associated with monotherapy of fluvoxamine. Eur J Hosp Pharm 2022. [DOI: 10.1136/ejhpharm-2022-003533] [Reference Citation Analysis]
13 Asadi Anar M, Foroughi E, Sohrabi E, Peiravi S, Tavakoli Y, Kameli Khouzani M, Behshood P, Shamshiri M, Faridzadeh A, Keylani K, Langari SF, Ansari A, Khalaji A, Garousi S, Mottahedi M, Honari S, Deravi N. Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1036093] [Reference Citation Analysis]
14 Lu LC, Chao CM, Chang SP, Lan SH, Lai CC. Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis. J Infect Public Health 2022;15:1259-64. [PMID: 36272390 DOI: 10.1016/j.jiph.2022.10.010] [Reference Citation Analysis]
15 Nakhaee H, Zangiabadian M, Bayati R, Rahmanian M, Ghaffari Jolfayi A, Rakhshanderou S. The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis. PLoS One 2022;17:e0267423. [PMID: 36201406 DOI: 10.1371/journal.pone.0267423] [Reference Citation Analysis]
16 Hoertel N, Sánchez-Rico M, Kornhuber J, Gulbins E, Reiersen AM, Lenze EJ, Fritz BA, Jalali F, Mills EJ, Cougoule C, Carpinteiro A, Mühle C, Becker KA, Boulware DR, Blanco C, Alvarado JM, Strub-Wourgaft N, Lemogne C, Limosin F, On Behalf Of Ap-Hp/Université Paris Cité/Inserm Covid-Research Collaboration Ap-Hp Covid Cdr Initiative And Entrepôt de Données de Santé Ap-Hp Consortium. Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19. J Clin Med 2022;11. [PMID: 36233753 DOI: 10.3390/jcm11195882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Wu G, Duan J. BLCov: A novel collaborative-competitive broad learning system for COVID-19 detection from radiology images. Eng Appl Artif Intell 2022;115:105323. [PMID: 35992036 DOI: 10.1016/j.engappai.2022.105323] [Reference Citation Analysis]
18 Fritz BA, Hoertel N, Lenze EJ, Jalali F, Reiersen AM. Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2. Transl Psychiatry 2022;12:341. [PMID: 35995770 DOI: 10.1038/s41398-022-02109-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
19 Papadopoulos KI, Papadopoulou A, Aw TC. Selective Serotonin Reuptake Inhibitors may Influence COVID-19 Prognosis through Antioxidant and Cytoprotective Pathways Mediated by Sigma 1 Receptor Agonism. Pharmacopsychiatry 2022. [PMID: 35981550 DOI: 10.1055/a-1909-2198] [Reference Citation Analysis]
20 Zhang JC, Yao W, Hashimoto K. Arketamine, a new rapid-acting antidepressant: A historical review and future directions. Neuropharmacology 2022;218:109219. [PMID: 35977629 DOI: 10.1016/j.neuropharm.2022.109219] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
21 Graham EL, Koralnik IJ, Liotta EM. Therapeutic Approaches to the Neurologic Manifestations of COVID-19. Neurotherapeutics 2022. [PMID: 35861926 DOI: 10.1007/s13311-022-01267-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wang YM, Xia CY, Jia HM, He J, Lian WW, Yan Y, Wang WP, Zhang WK, Xu JK. Sigma-1 receptor: A potential target for the development of antidepressants. Neurochem Int 2022;159:105390. [PMID: 35810915 DOI: 10.1016/j.neuint.2022.105390] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Wei Y, Chang L, Liu G, Wang X, Yang Y, Hashimoto K. Long-lasting beneficial effects of maternal intake of sulforaphane glucosinolate on gut microbiota in adult offspring. J Nutr Biochem 2022;:109098. [PMID: 35788394 DOI: 10.1016/j.jnutbio.2022.109098] [Reference Citation Analysis]
24 Ren P, Wang J, Li N, Li G, Ma H, Zhao Y, Li Y. Sigma-1 Receptors in Depression: Mechanism and Therapeutic Development. Front Pharmacol 2022;13:925879. [DOI: 10.3389/fphar.2022.925879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Sezer A, Halilović-Alihodžić M, Vanwieren AR, Smajkan A, Karić A, Djedović H, Šutković J. A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives. J Genet Eng Biotechnol 2022;20:78. [PMID: 35608704 DOI: 10.1186/s43141-022-00353-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Benedetti F, Zanardi R, Mazza MG. Antidepressant psychopharmacology: is inflammation a future target? Int Clin Psychopharmacol 2022;37:79-81. [PMID: 35357329 DOI: 10.1097/YIC.0000000000000403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
27 Nakhaee H, Bayati R, Rahmanian M, Jolfayi AG, Zangiabadian M, Rakhshanderou S. The effect of antidepressants on severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.. [DOI: 10.1101/2022.04.11.22273709] [Reference Citation Analysis]
28 Kálai T, Pongrácz JE, Mátyus P. Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine. Chemistry 2022;4:216-58. [DOI: 10.3390/chemistry4020019] [Reference Citation Analysis]
29 Le Corre P, Loas G. Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection. Front Pharmacol 2022;13:849095. [DOI: 10.3389/fphar.2022.849095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
30 Mühle C, Kremer A, Vetter M, Schmid J, Achenbach S, Schumacher F, Lenz B, Cougoule C, Hoertel N, Carpinteiro A, Gulbins E, Kleuser B, Kornhuber J. COVID-19 and its clinical severity are associated with alterations of plasma sphingolipids and enzyme activities of sphingomyelinase and ceramidase.. [DOI: 10.1101/2022.01.19.22269391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Shishkova V, Imamgayazova K, Kapustina L. Correction of psychoemotional disorders and short-term prognosis in patients with COVID-19. Z nevrol psikhiatr im S S Korsakova 2022;122:63. [DOI: 10.17116/jnevro202212205163] [Reference Citation Analysis]
32 Vai B, Mazza MG, Marisa CD, Beezhold J, Kärkkäinen H, Saunders J, Samochowiec J, Benedetti F, Leboyer M, Fusar-poli P, De Picker L. Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health. Eur Psychiatr 2022;65:e47. [DOI: 10.1192/j.eurpsy.2022.2307] [Reference Citation Analysis]
33 Hashimoto Y, Suzuki T, Hashimoto K. Comments to "Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists" by Khani and Entezari-Maleki. Mol Psychiatry 2022;27:3563-4. [PMID: 35388183 DOI: 10.1038/s41380-022-01546-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Khani E, Entezari-Maleki T. Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists. Mol Psychiatry 2022;27:3562. [PMID: 35388182 DOI: 10.1038/s41380-022-01545-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
35 Brennan BP, Schnabel J, Pope HG Jr, Hudson JI. Antidepressant use and risk of intubation or death in hospitalized patients with COVID-19: A retrospective cohort study of clinical effectiveness. Front Psychiatry 2022;13:951065. [PMID: 36186877 DOI: 10.3389/fpsyt.2022.951065] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Borovcanin MM, Vesic K, Balcioglu YH, Mijailović NR. Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution. Front Psychiatry 2022;13:1052710. [PMID: 36339865 DOI: 10.3389/fpsyt.2022.1052710] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Shishkova VN, Imamgayazova KE, Kapustina LA. Correction of Psychoemotional Disorders and Short-Term Prognosis in Patients with COVID-19. Neurosci Behav Physiol 2022;52:1373-8. [PMID: 36846621 DOI: 10.1007/s11055-023-01369-w] [Reference Citation Analysis]